Terns Pharmaceuticals, Inc. Capital Expenditures

Capital Expenditures of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital Expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital Expenditures for the quarter ending March 31, 2022 was $-242 Thousand (a 21.0% increase compared to previous quarter)
  • Year-over-year quarterly Capital Expenditures increased by 476.19%
  • Annual Capital Expenditures for 2021 was $-340 Thousand (a -41.78% decrease from previous year)
  • Annual Capital Expenditures for 2020 was $-584 Thousand (a -35.11% decrease from previous year)
  • Annual Capital Expenditures for 2019 was $-900 Thousand (a 268.85% increase from previous year)
  • Twelve month Capital Expenditures ending March 31, 2022 was $-558 Thousand (a 64.12% increase compared to previous quarter)
  • Twelve month trailing Capital Expenditures increased by 372.88% year-over-year
Trailing Capital Expenditures for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-558 Thousand $-340 Thousand $-187 Thousand $-118 Thousand
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital Expenditures of Terns Pharmaceuticals, Inc.

Most recent Capital Expendituresof TERN including historical data for past 10 years.

Interactive Chart of Capital Expenditures of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Capital Expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-0.24
2021 $-0.2 $-0.07 $-0.04 $-0.02 $-0.34
2020 $-0.05 $-0.01 $-0.1 $-0.43 $-0.58
2019 $-0.9 $-0.9
2018 $-0.24

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.